# Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria

> **NCT05314231** · PHASE1 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 13 (actual)

## Conditions studied

- Proteinuria

## Interventions

- **DRUG:** ALXN1720

## Key facts

- **NCT ID:** NCT05314231
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-29
- **Primary completion:** 2023-05-31
- **Final completion:** 2023-05-31
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2023-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05314231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05314231, "Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05314231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*